GE HealthCare has raised its fiscal year 2025 (FY25) profit outlook to between $3.02 and $3.04 per share amid solid demand across all of its business segments in Q3 2025.
Achieving revenues of $5.9bn in Q3, reflecting a 6% rise on Q3 2024, the imaging giant now expects profits of $4.51 to $4.63 per share, up from $4.43 at the low-end to $4.63 previously.
Patient Care Solutions and Pharmaceutical Diagnostics rose by 6% and 20% in Q3 to $731m and $749m, respectively. However, the lion’s share of revenue was down to GE HealthCare’s Imaging and Advanced Visualisation Solutions, with revenues rising by 5% and 7% to around $2.34bn and $1.3bn, respectively.
During its post-earnings conference call, GE HealthCare’s CEO, Peter Arduini highlighted that the company’s “synergistic portfolio” of diagnostic imaging equipment, radiopharmaceuticals, artificial intelligence (AI), cloud, and software was giving it a competitive advantage in the imaging space.
Arduini added that strong commercial execution, with multiple large system deals in Q3, would drive almost $500m in future revenue, thereby further strengthening its ongoing growth momentum.
Earlier this month, GE HealthCare inked a 14-year care alliance with UC San Diego Health, focused on early detection and advancing cancer care with imaging solutions and novel therapies such as theragnostics.
In September, GE HealthCare acquired AI-based brain imaging company icometrix to expand its magnetic resonance (MR) imaging capabilities for neurological disorders.
Arduini commented: “With the integration of icometrix technologies into our MR systems, we will strengthen our unique and comprehensive portfolio to support the full Alzheimer's care pathway. This is a great example of our D3 strategy at work: smart devices and imaging, and drugs in PDX enabled by AI to create meaningful value for our customers and patients while driving sustainable growth for the company.”
Arduini also highlighted that integrating technology like CaptionAI into its Vscan Air SL wireless handheld ultrasound system to provide real-time guidance for cardiac exams and upgrading its fleet of clinical subsystems into common platforms, had increased the margins of these new products compared to prior models.
Within the past six months, GE HealthCare has released software combining its own imaging functionalities with tools enabled by a platform developed by MIM Software, to enhance imaging workflows in indications including oncology and cardiology, and launched Vivid Pioneer, a new cardiovascular ultrasound system that integrates AI to enhance imaging speed and quality.
Asked about the company’s 2026 growth outlook since projecting organic growth for FY25 of 3%, GE HealthCare’s CFO, James Saccaro, said as it looks to 2026, its expectation would be to “grow faster” than 3%.
